- New Formulation of Rebif(R) Designed to Improve Injection Tolerability Merck Serono, a division of Merck KGaA, announced today that the European Commission has ...

MISSISSAUGA, ON, May 25, 2015 /CNW/ - Today, EMD Serono a Division of EMD Inc., Canada, a subsidiary of Merck KGaA, Darmstadt, Germany, announces that REBIF (interferon beta-1a), the company's disease ...

Merck Serono, a division of Merck, Darmstadt, Germany, announced today the forthcoming introduction of the new injection device RebiSlide™ in Europe and Canada, followed by other countries. RebiSlide™ ...

Serono SA released impressive 24-week data from its 677-patient, head-to-head study of its product Rebif vs. Biogen Inc. s Avonex in patients with relapsing-remitting multiple sclerosis, and is ...

DARMSTADT, Germany, October 18, 2017/PRNewswire/. Merck, a leading science and technology company, today announced that data for approved and investigational multiple sclerosis (MS) treatments, ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that new pregnancy outcomes data in women with MS treated with interferon beta (IFN β), including ...

The FDA has approved Rebif Rebidose, a single-use auto-injector prefilled with EMD Serono and Pfizer's ($PFE) interferon beta-1a, for the treatment of relapsing forms ...

Merck Serono has won approval from European regulators to sell a new formulation of its blockbuster Rebif for the treatment of relapsing multiple sclerosis. Merck Serono has won approval from European ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...

On September 20, the European Commission approved 30- and 45-mg strengths of oseltamivir phosphate capsules (Tamiflu, Hoffmann-La Roche Ltd) for the treatment and prevention of influenza types A and B ...

March 16, 2005 — The U.S. Food and Drug Administration (FDA) approved in December 2004 revisions to safety labeling to advise healthcare professionals of the following changes: use of interferon ...

Merck KGaA has been striking deals and pushing R&D in a bid to revive its slumping drug portfolio. But the company's recent efforts aren't bearing fruit--at least not yet. On Tuesday, the German ...